H1 2023 Financial Highlights

Neuroscience Key ongoing clinical-trial highlights TRIAL POPULATION PATIENTS DESIGN PRIMARY ENDPOINT STATUS IPN10200 Ax LANTIC Phase II NCT04821089 Moderate to severe upper 424 facial lines Dose escalation & dose finding versus Dysport or placebo Safety First patient commenced dosing Q1 2023 IPN 10200 Tx Dose escalation & Adult patients with LANTIMA upper-limb 209 Phase II NCT04752774 spasticity dose finding versus Dysport or placebo Safety First patient commenced dosing Q2 2023 IPSEN Innovation for patient care 31

View entire presentation